Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

Bleeding Disorders

26 July 2016 CSL Behring Presents Phase III Data for IDELVION® for Hemophilia B at the World Federation of Hemophilia 2016 World Congress

CSL Behring today announced new data from its Phase III PROLONG-9FP clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for treating hemophilia B.

> Read More
25 July 2016 CSL Behring Awards Emerging Coagulation Specialists Across the Globe to Support Advancements in the Care of Patients with Bleeding Disorders

CSL Behring today announced that the company has named five recipients of the 2016 CSL Behring Professor Heimburger Award for coagulation research at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla.

> Read More
19 July 2016 CSL Behring to Present New Data for IDELVION® and AFSTYLA® at the World Federation of Hemophilia 2016 World Congress

CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla., July 24 – 28, 2016.

> Read More
20 June 2016 AFSTYLA® – CSL Behring’s Novel Recombinant Factor VIII Single Chain Therapy for Hemophilia A – Now Available in the U.S.

Driven by its promise to save lives, CSL Behring announced today that AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A, is now available nationwide.

> Read More
26 May 2016 U.S. FDA Approves CSL Behring’s AFSTYLA®-- The First and Only Recombinant Factor VIII Single Chain Therapy for Hemophilia A

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.

> Read More
Page 2 of 21 First | Next | Last

Share
LinkedIn Twitter Facebook Google+